JOP20200055A1 - مركبات بيرازولو بيريميدينون واستخداماتها - Google Patents

مركبات بيرازولو بيريميدينون واستخداماتها

Info

Publication number
JOP20200055A1
JOP20200055A1 JOP/2020/0055A JOP20200055A JOP20200055A1 JO P20200055 A1 JOP20200055 A1 JO P20200055A1 JO P20200055 A JOP20200055 A JO P20200055A JO P20200055 A1 JOP20200055 A1 JO P20200055A1
Authority
JO
Jordan
Prior art keywords
compounds
relates
present
pyrazolopyrimidinone
pharmaceutical compositions
Prior art date
Application number
JOP/2020/0055A
Other languages
English (en)
Inventor
Leonard Sung
Hossein Ismaili
Yeeman K Ramtohul
Laura Gillard
Taras Rybak
Mariam Zaky
Stephane Ciblat
Vu Linh Ly
Franck Raeppel
George Edwin Katibah
Tucker Curran Roberts
Chudi Obioma Ndubaku
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of JOP20200055A1 publication Critical patent/JOP20200055A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات بيرازولو بيريميدينون. يتعلق الاختراع الحالي أيضًا بتركيبات صيدلية تحتوي على هذه المركبات وطرق لعلاج أمراض المناعة الذاتية والأمراض الالتهابية والأمراض التنكسية العصبية عن طريق إعطاء هذه المركبات والتركيبات الصيدلية إلى خاضع للعلاج في حاجة إليها. ويتعلق الاختراع أيضًا باستخدام مثل هذه المركبات في أغراض الأبحاث وغيرها من الأغراض غير العلاجية. الشكل 1
JOP/2020/0055A 2017-09-15 2018-09-14 مركبات بيرازولو بيريميدينون واستخداماتها JOP20200055A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762559482P 2017-09-15 2017-09-15
US201862633248P 2018-02-21 2018-02-21
US201862687769P 2018-06-20 2018-06-20
PCT/US2018/051014 WO2019055750A1 (en) 2017-09-15 2018-09-14 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
JOP20200055A1 true JOP20200055A1 (ar) 2020-03-10

Family

ID=65723108

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0055A JOP20200055A1 (ar) 2017-09-15 2018-09-14 مركبات بيرازولو بيريميدينون واستخداماتها

Country Status (22)

Country Link
US (1) US10738056B2 (ar)
EP (1) EP3681888A4 (ar)
JP (1) JP2020533376A (ar)
KR (1) KR20200032751A (ar)
CN (1) CN111212839A (ar)
AU (1) AU2018331456B2 (ar)
BR (1) BR112020003676A2 (ar)
CA (1) CA3075751A1 (ar)
CL (1) CL2020000544A1 (ar)
CO (1) CO2020002107A2 (ar)
CR (1) CR20200114A (ar)
DO (1) DOP2020000051A (ar)
EC (1) ECSP20018586A (ar)
IL (1) IL273236A (ar)
JO (1) JOP20200055A1 (ar)
MA (1) MA50256A (ar)
MX (1) MX2020002869A (ar)
PE (1) PE20210340A1 (ar)
PH (1) PH12020500500A1 (ar)
SG (1) SG11202002218VA (ar)
TW (1) TW201920185A (ar)
WO (1) WO2019055750A1 (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019002303A (es) 2016-08-31 2019-07-15 Agios Pharmaceuticals Inc Inhibidores de procesos metabolicos celulares.
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
EP3707151B1 (en) 2017-11-10 2022-01-05 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
CA3084569A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
EP4017593A1 (en) * 2019-08-21 2022-06-29 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
CN110627725B (zh) * 2019-10-14 2022-10-18 遵义医科大学 一种4-取代5-二氟甲基-3-硝基-1h-吡唑类化合物及其制备方法与应用
MX2022006281A (es) 2019-11-25 2022-06-08 Amgen Inc Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
CN113248491B (zh) * 2020-02-11 2022-02-25 中国科学院上海药物研究所 一类取代的吲哚脲衍生物、合成方法及其用途
EP4153593A1 (en) * 2020-05-20 2023-03-29 F. Hoffmann-La Roche AG Cgas inhibiting triazolopyrimidone derivatives
JP2023525909A (ja) * 2020-05-20 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 新規マロニトリル誘導体
EP4153577A1 (en) * 2020-05-20 2023-03-29 F. Hoffmann-La Roche AG New malonitrile derivatives
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
CN114644633A (zh) * 2020-12-18 2022-06-21 北京诺诚健华医药科技有限公司 杂环类jak抑制剂
WO2022137082A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
WO2022221188A1 (en) * 2021-04-13 2022-10-20 University Of Washington Designed constitutively active cyclic gmp-amp synthase as a genetically encoded stimulant of interferons

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS625362A (ja) 1985-06-30 1987-01-12 菊地　真 ハイパ−サ−ミア用加温装置
JPH02131235A (ja) 1988-11-12 1990-05-21 Fuji Photo Film Co Ltd 新規なカプラーを含有するハロゲン化銀写真感光材料
WO1992006096A1 (en) 1990-10-09 1992-04-16 Otsuka Pharmaceutical Co., Ltd. Pyrimidine derivative, production thereof, and androgen inhibitor
WO1992018504A1 (fr) * 1991-04-22 1992-10-29 Otsuka Pharmaceutical Factory, Inc. DERIVE DE PYRAZOLO[1,5-a]PYRIMIDINE ET AGENT ANTI-INFLAMMATOIRECONTENANT CE DERIVE
KR100260292B1 (ko) 1995-09-28 2000-07-01 오쓰카 요시미쓰 진통제
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
TW495509B (en) * 1997-03-14 2002-07-21 Otsuka Pharma Co Ltd Novel pyrimidine derivative
JP3625362B2 (ja) 1997-09-08 2005-03-02 コニカミノルタホールディングス株式会社 感熱転写記録材料及び感熱転写記録方法
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2445515A1 (en) 2001-05-04 2002-11-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
ATE389656T1 (de) 2002-06-04 2008-04-15 Neogenesis Pharmaceuticals Inc Pyrazolo(1,5-a)pyrimidin-verbindungen als antivirale agentien
EP1558341A4 (en) 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
EP1742637A4 (en) 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
JP5344637B2 (ja) 2007-08-14 2013-11-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 縮合二環式ピリミジン
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009071705A1 (en) * 2007-12-07 2009-06-11 Galapagos Nv Pyrazolepyrimidine compounds useful for the treatment of degenerative & inflammatory diseases
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
EP2231671B1 (en) 2007-12-13 2013-04-24 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN101906105B (zh) 2009-06-08 2013-01-16 河北医科大学 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
ES2626006T3 (es) * 2010-08-12 2017-07-21 Boehringer Ingelheim International Gmbh Derivados de 6-cicloalquil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como inhibidores de PDE9A
AU2011310713A1 (en) 2010-09-27 2013-04-11 Proximagen Ltd 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as CCR2 receptor antagonists
WO2012149157A2 (en) * 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
MX2014014109A (es) 2012-05-23 2016-03-31 Savira Pharmaceuticals Gmbh Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral.
EP2864338B1 (en) 2012-05-23 2016-12-14 Savira Pharmaceuticals GmbH 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
CN104619699A (zh) 2012-08-06 2015-05-13 萨维拉制药有限公司 二羟基嘧啶碳酸衍生物以及它们在治疗、改善或预防病毒疾病中的用途
MX2015011898A (es) 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
MX2016002794A (es) * 2013-09-05 2016-09-13 Genentech Inc Compuestos antiproliferativos.
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
EP3148986A4 (en) 2014-05-27 2018-01-10 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
US10787462B2 (en) 2015-10-23 2020-09-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11414385B2 (en) 2015-12-21 2022-08-16 The University Of Chicago Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
AU2017251155B2 (en) 2016-04-15 2021-08-05 Bayer Animal Health Gmbh Pyrazolopyrimidine derivatives
WO2017210678A1 (en) 2016-06-03 2017-12-07 An2H Discovery Limited Pyrazolopyrimidine derivatives and the compositions and methods of treatment regarding the same
MX2019002303A (es) 2016-08-31 2019-07-15 Agios Pharmaceuticals Inc Inhibidores de procesos metabolicos celulares.
WO2018039972A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
CN111886225A (zh) * 2017-08-21 2020-11-03 纳维根公司 Arf6抑制剂及相关方法

Also Published As

Publication number Publication date
US20190119285A1 (en) 2019-04-25
CA3075751A1 (en) 2019-03-21
CR20200114A (es) 2020-06-01
PE20210340A1 (es) 2021-02-22
KR20200032751A (ko) 2020-03-26
SG11202002218VA (en) 2020-04-29
MA50256A (fr) 2020-07-22
PH12020500500A1 (en) 2021-03-01
EP3681888A4 (en) 2021-07-07
EP3681888A1 (en) 2020-07-22
TW201920185A (zh) 2019-06-01
CN111212839A (zh) 2020-05-29
AU2018331456A1 (en) 2020-03-05
MX2020002869A (es) 2020-07-24
AU2018331456B2 (en) 2020-10-08
DOP2020000051A (es) 2020-08-15
JP2020533376A (ja) 2020-11-19
ECSP20018586A (es) 2020-06-30
BR112020003676A2 (pt) 2020-09-01
WO2019055750A1 (en) 2019-03-21
US10738056B2 (en) 2020-08-11
CO2020002107A2 (es) 2020-05-29
IL273236A (en) 2020-04-30
CL2020000544A1 (es) 2020-10-02

Similar Documents

Publication Publication Date Title
JOP20200055A1 (ar) مركبات بيرازولو بيريميدينون واستخداماتها
MX2020001513A (es) Agentes de union a clec9a y su uso.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201792047A1 (ru) Новые соединения
PH12015500825A1 (en) Substituted benzene compounds
JOP20220245A1 (ar) أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة
MX344530B (es) Compuestos de benceno substituido.
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
NZ739867A (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
MX2018004220A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
MX2018004217A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases